PERCEPTIVE ADVISORS LLC
Q2 2023 13F-HR/A Holdings
Net value change ($000)
+67,827
(2.0%)
New positions
12
Sold out positions
22
Turnover %
15.7%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q1 2023
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| Cerevel Therapeutics Holdings, Inc. | 161,859 | 101.9% |
| AKRO | 70,580 | 352.4% |
| VIR | 44,727 | 1351.7% |
| MDT | 41,143 | NEW |
| FOLD | 40,664 | 13.3% |
| MGTX | 40,164 | 111.6% |
| VRNA | 38,060 | 69.3% |
| APLS | 37,347 | 102.0% |
| PCVX | 36,757 | 83.8% |
| LYRA | 34,049 | 185.2% |
Top Reduces (Value $000, Stocks/ETFs)
| Prometheus Biosciences, Inc. | -136,586 | -100.0% |
| REATA PHARMACEUTICALS INC | -128,897 | -65.4% |
| MDGL | -87,615 | -55.6% |
| AMLX | -71,926 | -40.6% |
| BMRN | -42,633 | -65.1% |
| SNY | -41,800 | -100.0% |
| BELLUS Health Inc. | -35,658 | -100.0% |
| Mirati Therapeutics, Inc. | -32,545 | -55.6% |
| OBIO | -30,215 | -67.8% |
| SRPT | -26,669 | -74.2% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
13,013
(0.4% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|